Susceptibility to azoles and amphotericin B of isolates of Candida spp. Experience of a university health network, between 2004 and 2010;Susceptibilidad a azoles y anfotericina B de aislados de Candida spp. Experiencia de una red de salud universitaria, entre 2004 y 2010

Revista Chilena de Infectologia

Volumn 29, Issue 2, 2012, Pages 149-155

  Porte, Lorena ^a,c   León, Pilar ^a   Gárate, Cynthia ^a   Guzmán, Ana María ^a   Labarca, Jaime ^b   García, Patricia ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^c HOSPITAL MILITAR DE SANTIAGO   (Chile)

Author keywords

Amphotericin B; Candida; Drug resistance; Fluconazole; Voriconazole

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ARTICLE; CANDIDA; CHILE; CLASSIFICATION; COHORT ANALYSIS; DRUG EFFECT; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; RETROSPECTIVE STUDY;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDA; CHILE; COHORT STUDIES; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; HUMANS; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; RETROSPECTIVE STUDIES; TRIAZOLES;

EID: 84861941228     PISSN: 07161018     EISSN: None     Source Type: Journal    
DOI: 10.4067/S0716-10182012000200005     Document Type: Article

References (30)

1. Pfaller M A, Diekema D J. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20: 133-63.
2. Kiraz N, Dag I, Oz Y, Yamac M, Kiremitci A, Kasifoglu N. Correlation between broth microdilution and disk diffusion methods for antifungal susceptibility testing of caspofungin, voriconazole, amphotericin B, itraconazole and fl uconazole against Candida glabrata. J Microbiol Methods 2010; 82: 136-40.
3. Lass-Fiörl C, Perkhofer S, Mayr A. In vitro susceptibility testing in fungi: a global perspective on a variety of methods. Mycoses 2010; 53: 1-11.
4. CLSI. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard-Third Edition. M27-A3 Vol. 28 No. 14, 2008.
5. CLSI. Reference method for broth dilution antifungal susceptibility testing of yeasts; Third informational supplement. M27-S3 Vol. 28 No. 15, April 2008.
6. Motta A L, Almeida G M, Almeida Júnior J N, Burattini M N, Rossi F. Candidemia epidemiology and susceptibility profi le in the largest Brazilian teaching hospital complex. Braz J Infect Dis 2010; 14 (5): 441-8.
7. Cruz R, Piontelli E. Enfermedad fúngica invasora en pacientes de cinco hospitales de la Región de Valparaíso, Chile. 2004 a 2009. Rev Chil Infectol 2011; 28 (2): 123-9.
8. Silva V, Díaz MC, Febré N y Red de Diagnóstico en Micología Médica. Vigilancia de la resistencia de levaduras a antifúngicos. Rev Chil Infectol 2002; 19: 149-56.
9. Ajenjo MC, Aquevedo S, Guzmán AM, Poggi H, Calvo M, Castillo C, et al. Perfi l epidemiológico de la candidiasis invasora en unidades de pacientes críticos en un hospital universitario. Rev Chil Infectol 2011; 28(2): 118-22.
10. Pfaller M A, Jones R N, Doern G, Sader H S, Hollis R J, Messer S A, for the Sentry Participant Group. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada and South America for the SENTRY Program. J Clin Microbiol 1998; 36: 1886-9.
11. Alvarado D, Díaz M C, Silva V. Identifi cación y susceptibilidad antifúngica de Candida spp. aisladas de micosis invasora. Infl uencia del porcentaje de inhibición de crecimiento para la determinación de la CIM. Rev Med Chile 2002; 130 (4): 416-23.
12. Silva V, Díaz M C, Febré N, and Chilean Invasive Infection Group. Invasive fungal infections in Chile: a multicenter study of fungal prevalence and susceptibility during a 1-year period. Med Mycol 2004; 42: 333-9.
13. Alburquerque C, Hermosilla G, Tapia C. Distribución y susceptibilidad a fl uconazol de levaduras del género Candida aisladas en pacientes hospitalizados y ambulatorios. Rev Chil Infectol 2009; 26 (5): 435-39.
14. Bourgeois N, Dehandschoewercker L, Bertout S, Bousquet P, Rispail P, Lachaud L. Antifungal susceptibility of 205 Candida spp. isolated primarily during invasive candidiasis and comparison of the Vitek 2 system with the CLSI broth microdilution and E test methods. J Clin Microbiol 2010; 48 (1): 154-61.
15. Pfaller M, Diekema D, Gibbs D, Newell V, Barton R, Bijie H, et al. Geographic variation in the frequency of isolation and fl uconazole and voriconazole susceptibilities of Candida glabrata: an assessment from the ARTEMIS DISK global antifungal surveillance program. Diagn Microbiol Infect Dis 2010; 67: 162-71.
16. Laverdiere M, Lalonde R G, Baril J G, Sheppard D C, Park S, Perlin D. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother 2006; 57: 705-8
17. Hernandez S, Lopez-Ribot JL, Najvar LK, McCarthy DI, Bocanegra R, Graybill JR. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob Agents Chemother 2004; 48: 1382-3.
18. Thompson III G, Wiederhold N, Vallor A, Villareal N, Lewis II J, Patterson T. Antimicrob Agents Chemother 2008; 52 (10): 3783-5.
19. Hakki M, Staab J F, Marr K A. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob Agents Chemother 2006; 50: 2522-4.
20. Moudgal V, Little T, Boikov D y Vazquez J. Multiechinocandin and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother 2005; 49: 767-9.
21. St-Germain G, Laverdière M, Pelletier R, René P, Bourgault AM, Lemieux C, et al. Epidemiology and antifungal susceptibility of bloodstream Candida isolates in Quebec: report on 453 cases between 2003 and 2005. Can J Infect Dis Med Microbiol 2008; 19 (1): 55-62.
22. thed. Washington, D.C., ASM Press; 2007, p. 1949-71.
23. Moran G, Sullivan D, Coleman D. Chapter 4: Emergence of non-Candida albicans Candida species as pathogens. En Calderone R, ed. Candida and candidiasis, Washington, D.C., ASM Press; 2002, p. 41. http://books.google.cl/, 16/01/2011.
24. Pfaller M, Diekema D. Twelve years of fl uconazole in clinical practice: global trends in species distribution and fl uconazole susceptibility of bloodstream isolates of Candida. Clin Microbiol Infect 2004; 10: 11-23.
25. Sabatelli F, Patel R, Mann P A, Mendrick C A, Norris C C, Hare R, et al. In vitro activities of posaconazole, fl uconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006; 50 (6): 2009-15.
26. Pfaller M, Diekema D, Mendez M, Kibbler C, Erzsebet P, Chang S-C, et al. Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fl uconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program. J Clin Microbiol 2006; 44 (10): 3551-6.
27. Pfaller M A, Diekema D J, Andes D, Arendrup M C, Brown S D, Lockhart S R, et al. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive all species-specifi c interpretative criteria. Drug Resistance Updates 2011; 14: 164-76.
28. Pfaller M A, Andes D, Diekema D J, Espinel-Ingroff A, Sheehan D. Wild-type MIC distributions, epidemiological cut-off values and species-specifi c clinical breakpoints for fl uconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilutions methods. Drug Resistance Updates 2010; 13: 180-95.
29. Pfaller M A, Andes D, Arendrup M C, Diekema D J, Espinel-Ingroff A, Alexander B, et al. Clinical breakpoints for voriconazole and Candida spp. Revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specifi c interpretative criteria. Diagn Microbiol Infect Dis 2011; 70: 330-43.
30. Cuenca-Estrella M, Gómez-López A, Alastruey-Izquierdo A, Bernal-Martínez L, Cuesta I, Buitrago M, et al. Comparison of the Vitek 2 antifungal susceptibility system with the Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) broth microdilution reference methods and with the Sensititre YeastOne and E-test techniques for in vitro detection of antifungal resistance in yeast isolates. J Clin Microbiol 2010; 48 (5): 1782-6.